Statistical considerations in a delayed-start design to demonstrate disease modification effect in neurodegenerative disorders-Reference-Cited by-同舟云学术

Statistical considerations in a delayed-start design to demonstrate disease modification effect in neurodegenerative disorders

Published:2019-01-29 Issue:4 Volume:18 Page:407-419
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Wang Deli¹^ORCID,Robieson Weining¹,Zhao Jun²,Wiener Catherine³,Koch Gary³

Affiliation:

1. Data and Statistical Sciences; AbbVie Inc; North Chicago Illinois USA

2. Data Science, Astellas Pharma Global Development; 1 Astellas Way Northbrook IL 60062 USA

3. Department of Biostatistics; The University of North Carolina; Chapel Hill North Carolina USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pst.1931/fullpdf

Reference24 articles.

1. The National Institute of Neurological Disorders and Stroke Parkinson's disease information page https://www.ninds.nih.gov/Disorders/All-Disorders/Parkinsons-Disease-Information-Page 2016

2. Drugs aging;Henchcliffe;Ther Adv Neurol Diso,2011

3. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria;Dubois;Lancet Neurol,2014

4. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria;Dubois;Alzheimer's & Dementia,2016

5. Committee for Medicinal Products for Human Use (CHMP) Guidance on the clinical investigation of medicines for the treatment of Alzheimer's disease 2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Are lecanemab and donanemab disease‐modifying therapies?;Alzheimer's & Dementia;2024-08-03

2. A randomized, double‐blind, placebo‐controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis;European Journal of Neurology;2023-08-21

3. How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson’s disease?;Expert Review of Neurotherapeutics;2023-02-01

4. Considerations for clinical trial design and conduct in the evaluation of novel advanced therapeutics in neurodegenerative disease;International Review of Neurobiology;2022

5. Environment, lifestyle, and Parkinson's disease: Implications for prevention in the next decade;Movement Disorders;2019-05-15